RA

RaySearch Laboratories AB (publ)STO RaySearch Laboratories Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

0.26

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

RAY B.ST Stock Analysis

RA

Uncovered

RaySearch Laboratories AB (publ) is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

88/100

Moderate score

Market cap $B

0.26

Dividend yield

1.37 %

Shares outstanding

25.83 B

RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

View Section: Eyestock Rating